Cargando…

The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience

Treatment with radiolabelled somatostatin analogs, a form of peptide receptor radionuclide therapy (PRRT), has changed the management of patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). There is a subgroup of patients who have suboptimal benefit and rapidly progress on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohamed, Amr, Asa, Sylvia L., Lee, Zhenghong, Tirumani, Sree H., Li, Qiubai, Avril, Norbert, Bajor, David, Mahipal, Amit, Chakrabarti, Sakti, Selfridge, J. Eva, Kardan, Arash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186532/ https://www.ncbi.nlm.nih.gov/pubmed/37201086 http://dx.doi.org/10.21037/jgo-22-1011

Ejemplares similares

The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs)
por: Mohamed, Amr, et al.
Publicado: (2022)

Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination
por: Mohamed, Amr, et al.
Publicado: (2022)

Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines
por: Mohamed, Amr, et al.
Publicado: (2022)

GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETs) - APPROACH TO DIAGNOSIS AND MANAGEMENT
por: Oladejo, A.O.
Publicado: (2009)

mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)
por: Zanini, Sara, et al.
Publicado: (2020)

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness
por: Barrea, Luigi, et al.
Publicado: (2018)

Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
por: Kaliszewski, Krzysztof, et al.
Publicado: (2022)

PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity
por: Ferrata, Martina, et al.
Publicado: (2019)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
por: Uri, Inbal, et al.
Publicado: (2018)

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014
por: Garcia-Carbonero, R., et al.
Publicado: (2014)

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
por: Kim, Seung Tae, et al.
Publicado: (2016)

Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study
por: Cho, Mee-Yon, et al.
Publicado: (2012)

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues
por: Anthony, Lowell B., et al.
Publicado: (2021)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors
por: Gallicchio, Rosj, et al.
Publicado: (2023)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development
por: Garcia-Carbonero, Rocio, et al.
Publicado: (2015)

Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Hee Sung, et al.
Publicado: (2011)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies
por: Diamantopoulos, Leonidas N., et al.
Publicado: (2023)

Relationship between somatostatin receptor expressing tumour volume and health‐related quality of life in patients with metastatic GEP‐NET
por: Ohlsson, Håkan, et al.
Publicado: (2022)

Initial evaluation of inflammatory breast cancer with fluorodeoxyglucose positron emission tomography
por: Sager, Sait, et al.
Publicado: (2012)

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
por: Chakrabarti, Sakti, et al.
Publicado: (2020)

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

Somatostatin Receptor-negative and Fluorodeoxyglucose-positron Emission Tomography-positive Lung Neuroendocrine Tumor G1 Exhibiting Cyclic Cushing's Syndrome
por: Nomura, Chiaki, et al.
Publicado: (2022)

Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient–Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context
por: Wagner, Monika, et al.
Publicado: (2018)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy
por: Cox, Ronald E, et al.
Publicado: (2021)

The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review
por: Chakrabarti, Sakti, et al.
Publicado: (2020)

THU526 Long-term Follow-up Of A Functional Gastroenteropancreatic Tumor Secreting Both Somatostatin And Gastrin
por: Zafar, Rafia, et al.
Publicado: (2023)

Development of a Framework Based on Reflective MCDA to Support Patient–Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States
por: Wagner, Monika, et al.
Publicado: (2017)

Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation
por: Binderup, Tina, et al.
Publicado: (2013)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions
por: Chakrabarti, Sakti, et al.
Publicado: (2020)

Hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumors (PTHrP-PNETs): Case Report
por: Pitts, Stephanie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pl2id192v4bfiubfa01hg58br5